Novavax, Inc. (NASDAQ:NVAX - Free Report) - Research analysts at Zacks Research cut their Q1 2025 EPS estimates for Novavax in a note issued to investors on Wednesday, February 26th. Zacks Research analyst S. Ganoria now forecasts that the biopharmaceutical company will post earnings of ($0.65) per share for the quarter, down from their prior forecast of ($0.63). The consensus estimate for Novavax's current full-year earnings is ($1.46) per share. Zacks Research also issued estimates for Novavax's Q2 2025 earnings at $0.38 EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.83) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.00 EPS and FY2026 earnings at $0.31 EPS.
Several other equities research analysts also recently weighed in on NVAX. TD Cowen raised shares of Novavax to a "hold" rating in a report on Thursday, February 27th. BTIG Research began coverage on shares of Novavax in a report on Friday, February 28th. They set a "buy" rating and a $19.00 price target on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Novavax presently has an average rating of "Hold" and an average price target of $18.00.
Get Our Latest Stock Analysis on NVAX
Novavax Price Performance
NVAX traded up $0.46 during trading hours on Monday, hitting $8.33. 3,153,115 shares of the stock were exchanged, compared to its average volume of 8,070,101. The stock has a 50-day simple moving average of $8.46 and a 200-day simple moving average of $9.85. Novavax has a 12 month low of $3.81 and a 12 month high of $23.86. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -3.69, a price-to-earnings-growth ratio of 2.85 and a beta of 2.14.
Novavax (NASDAQ:NVAX - Get Free Report) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.24. The company had revenue of $88.31 million for the quarter, compared to analysts' expectations of $85.48 million. During the same quarter in the previous year, the business posted ($1.44) earnings per share.
Insider Transactions at Novavax
In related news, Director Rachel K. King sold 4,150 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the transaction, the director now directly owns 14,770 shares in the company, valued at approximately $133,225.40. This trade represents a 21.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James F. Young sold 4,600 shares of Novavax stock in a transaction on Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total transaction of $39,008.00. Following the completion of the sale, the director now owns 57,160 shares in the company, valued at $484,716.80. The trade was a 7.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,150 shares of company stock worth $119,641 in the last quarter. 1.00% of the stock is owned by company insiders.
Hedge Funds Weigh In On Novavax
Several large investors have recently modified their holdings of NVAX. GF Fund Management CO. LTD. bought a new position in Novavax during the fourth quarter worth about $27,000. Spire Wealth Management bought a new position in shares of Novavax during the fourth quarter worth approximately $29,000. New Age Alpha Advisors LLC acquired a new stake in shares of Novavax in the fourth quarter valued at approximately $35,000. KBC Group NV boosted its stake in shares of Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock valued at $64,000 after buying an additional 3,917 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Novavax by 38.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company's stock worth $77,000 after buying an additional 1,598 shares in the last quarter. 53.04% of the stock is owned by institutional investors.
About Novavax
(
Get Free Report)
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Further Reading
Before you consider Novavax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.
While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
